Ex-FDA head: End barriers between devices, Dx and drugs

Too many financial and regulatory obstacles separate device, diagnostics and drug companies as they develop new treatments. And so they should be working together and sharing intellectual property at a much earlier point in their research, argues Dr. Andrew von Eschenbach, who ran the FDA from 2005 to 2009. According to the Boston Business Journal/Mass High Tech, Eschenbach urged a massive overhaul in the regulatory and financial arms that fuel biomedical development in order to promote more collaboration earlier in the process. "You need to be collaborating and sharing intellectual property at the very onset," he told a crowd at a Medical Development Group-sponsored seminar, as highlighted by the BBJ/MHT. "Today, there are huge barriers to doing that." Story

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.